An Observational Study Evaluating the Productivity and Health-Related Quality of Life of People With HER2 Positive Breast Cancer

  • Breast Cancer HER-2 Positive
Trial Status:


This trial runs in
  • Abergavenny
  • Colchester
  • Exeter
  • Guildford
  • Ipswich
  • London
  • Manchester
  • Newcastle upon Tyne
  • Northwood
  • Nottingham
  • Truro
  • Wakefield
  • Yeovil
Trial Identifier:

NCT03099200 ML30098

      Show trial locations

      The source of the below information is the publicly available website It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      The purpose of this study is to compare productivity (in terms of work or daily activity) and generic and disease-specific health-related quality of life of participants with HER2 positive early breast cancer currently receiving adjuvant treatment (with chemotherapy and/or targeted HER2 therapy), with participants who have completed adjuvant parenteral therapy, and participants with HER2 positive metastatic breast cancer.

      Hoffmann-La Roche Sponsor
      NCT03099200 , ML30098 Trial Identifier
      No Intervention Treatments
      Breast Neoplasms Condition
      Official Title

      UK HER2 Positive Breast Cancer Productivity & Utility Non-Interventional Study (PURPOSE)

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Diagnosed with early stage or metastatic (Stage IV) HER2-positive breast cancer (confirmed by the study site physician). [HER2-positive is defined as ImmunoHistoChemistry (IHC3+) and/or in situ hybridization (ISH) ≥2.0]
      • Able to provide written, informed consent.
      • Early Stage Breast Cancer (eBC) patients must have received at least 1 cycle of adjuvant anti-cancer therapy following surgery; metastatic breast cancer (mBC) patients must have received at least 1 cycle of treatment for their metastatic disease.
      Exclusion Criteria
      • Unwilling or unable to consent.
      • Unable to complete written quality of life questionnaires
      • Partcipants with Eastern Cooperative Oncology Group (ECOG) Performance Status ≥3

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now